Centocor Novel Psoriasis Biologic On Track Following Positive Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson subsidiary reports positive results of a Phase III study evaluating the monoclonal antibody targeting interleukin 12 and interleukin 23.
You may also be interested in...
J&J Pipeline On Track; Tapentadol Filing Expected This Week
Firm reports fourth quarter pharmaceutical sales of $6.4 billion worldwide and $3.9 billion in the U.S.
J&J Pipeline On Track; Tapentadol Filing Expected This Week
Firm reports fourth quarter pharmaceutical sales of $6.4 billion worldwide and $3.9 billion in the U.S.
Abbott’s Humira Gets FDA Nod For Adult Plaque Psoriasis
A crowded market for Humira’s fifth indication fails to intimidate Abbott, which envisions the drug as a “formidable competitor” in chronic adult plaque psoriasis, firm tells “The Pink Sheet” DAILY.